Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IDYA 
Ideaya Biosciences Inc (IDYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: IDYA (3-star) is a REGULAR-BUY. BUY since 93 days. Simulated Profits (20.22%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $46.88
1 Year Target Price $46.88
| 10 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 83.02% | Avg. Invested days 55 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.16B USD | Price to earnings Ratio - | 1Y Target Price 46.88 |
Price to earnings Ratio - | 1Y Target Price 46.88 | ||
Volume (30-day avg) 13 | Beta 0.12 | 52 Weeks Range 13.45 - 37.80 | Updated Date 09/14/2025 |
52 Weeks Range 13.45 - 37.80 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5488.94% |
Management Effectiveness
Return on Assets (TTM) -23.84% | Return on Equity (TTM) -35.09% |
Valuation
Trailing PE - | Forward PE 4.65 | Enterprise Value 1513770112 | Price to Sales(TTM) 308.13 |
Enterprise Value 1513770112 | Price to Sales(TTM) 308.13 | ||
Enterprise Value to Revenue 216.25 | Enterprise Value to EBITDA -7.8 | Shares Outstanding 87643696 | Shares Floating 81816257 |
Shares Outstanding 87643696 | Shares Floating 81816257 | ||
Percent Insiders 0.91 | Percent Institutions 115.11 |
Upturn AI SWOT
Ideaya Biosciences Inc
Company Overview
History and Background
Ideaya Biosciences Inc. was founded in 2010. The company focuses on discovering and developing targeted oncology therapeutics. It has evolved from a research-focused organization to a clinical-stage biopharmaceutical company.
Core Business Areas
- Small Molecule Discovery and Development: Focuses on identifying and developing small molecule inhibitors that target critical pathways in cancer cells.
- Synthetic Lethality: Utilizes synthetic lethality approaches to target tumors with specific genetic mutations or dependencies.
- Preclinical and Clinical Research: Conducts preclinical studies and clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
Darren Eckert is the current CEO. The company has a board of directors and various functional departments including research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- IDE196 (Darovasertib): A protein kinase C (PKC) inhibitor being developed for genetically defined cancers, including metastatic uveal melanoma (MUM). Market share data is not publicly available. Competitors in this area include companies developing targeted therapies for MUM. Revenue from this product is not yet available.
- IDE397 (MAT2A inhibitor): A small molecule inhibitor of methionine adenosyltransferase 2A (MAT2A) being developed for tumors with methylthioadenosine phosphorylase (MTAP) deletions. Market share data is not publicly available. Competitors include other companies pursuing MAT2A or related targets. Revenue from this product is not yet available.
- Vactosertib (TGF-beta inhibitor): Ideaya Biosciences is studying this in combination with other treatments. Market share data is unavailable. Main competitors are other TGF-beta inhibitors in the market, such as Debio 0123. Revenue is currently not available.
Market Dynamics
Industry Overview
The oncology therapeutics market is characterized by intense competition, rapid innovation, and high regulatory hurdles. It's driven by the growing incidence of cancer and advancements in personalized medicine.
Positioning
Ideaya Biosciences is positioned as a company focused on precision medicine and synthetic lethality approaches, targeting specific genetic vulnerabilities in cancer. Its competitive advantage lies in its expertise in these areas and its pipeline of novel drug candidates.
Total Addressable Market (TAM)
The oncology therapeutics market is estimated to be worth hundreds of billions of dollars. Ideaya Biosciences is positioned to capture a portion of this TAM by developing targeted therapies for specific cancer subtypes.
Upturn SWOT Analysis
Strengths
- Strong expertise in synthetic lethality and precision medicine
- Proprietary drug discovery platform
- Pipeline of novel drug candidates targeting specific genetic vulnerabilities in cancer
- Strategic collaborations with leading pharmaceutical companies
Weaknesses
- Clinical trial risk and regulatory hurdles
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on key partnerships
- No approved products generating revenue
Opportunities
- Expansion of pipeline through internal discovery and external collaborations
- Potential for breakthrough therapies in genetically defined cancers
- Partnerships with larger pharmaceutical companies for late-stage development and commercialization
- Acquisition by a larger pharmaceutical company
Threats
- Competition from larger pharmaceutical companies with more resources
- Failure of clinical trials
- Regulatory setbacks
- Patent challenges
- Economic downturn affecting funding for biotechnology companies
Competitors and Market Share
Key Competitors
- Mirati Therapeutics Inc (MRTX)
- Repare Therapeutics Inc (RPTX)
- Kura Oncology Inc (KURA)
Competitive Landscape
Ideaya faces competition from other biotechnology and pharmaceutical companies developing targeted oncology therapeutics. Its competitive advantage lies in its focus on synthetic lethality and precision medicine approaches. All the competitors in the Market Share Comparison are at the same clinical stage
Growth Trajectory and Initiatives
Historical Growth: Ideaya Biosciences' historical growth has been characterized by the expansion of its pipeline and the establishment of strategic collaborations.
Future Projections: Future growth is dependent on the success of its clinical trials, regulatory approvals, and the expansion of its pipeline. Analyst estimates vary but generally project revenue growth based on potential product launches and continued collaboration revenue.
Recent Initiatives: Recent strategic initiatives include advancing its lead drug candidates through clinical trials, expanding its collaborations with pharmaceutical companies, and exploring new therapeutic targets.
Summary
Ideaya Biosciences is a clinical-stage biopharmaceutical company with a focus on precision medicine for oncology. Its strengths lie in its expertise in synthetic lethality and its pipeline of novel drug candidates. The company faces challenges typical of clinical-stage biotechs, including clinical trial risk and limited financial resources. Ideaya needs to manage its cash runway and partnership dependencies to achieve its goals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated and may not be precise. Financial performance is as of the last available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ideaya Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-05-23 | Founder, President, CEO & Director Mr. Yujiro S. Hata | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://www.ideayabio.com |
Full time employees 131 | Website https://www.ideayabio.com | ||
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.